Media2017-10-24T20:47:01-07:00

Forge Therapeutics receives notice of allowance from U.S. patent and trademark office covering novel chemistry targeting LpxC for the treatment of gram-negative bacterial infections

-Issuance of patent demonstrates utility of Forge’s BLACKSMITH chemistry platform-San Diego, California, Aug 14, 2019 [...]

August 14th, 2019|

Forge Receives Second CARB-X Award For Up To $11.1M To Accelerate Development Of Novel Antibiotic To Treat Lung Infections

  San Diego, California, January 3, 2019 – Forge Therapeutics, Inc. (Forge), a biotechnology company [...]

January 3rd, 2019|

Forge achieves carb-x milestone to advance its lpxc antibiotic to treat infections caused by the world’s deadliest ‘superbugs’

-Technical milestone achievement and program advancement from initial round of ‘Powered by CARB-X’ products- San [...]

August 1st, 2018|

Categories

Archives

Recent Tweets